Vertex Pharmaceuticals (NASDAQ: VRTX) and AC Immune (NASDAQ: ACIU): which one is better

Vertex Pharmaceuticals (NASDAQ: VRTX) and AC Immune (NASDAQ: ACIU) are both medical firms, but which one is the superior? Based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings we will compare the two companies.

94.9 per cent of Vertex Pharmaceuticals shares are owned by institutional investors. In comparison, institutional investors own 27.8 per cent of AC Immune shares. Insiders own 0.7 per cent of Vertex Pharmaceuticals ‘ shares. High institutional ownership is an indicator of the long-term outperformance of a company by large money managers, endowments and hedge funds.

Vertex Pharmaceuticals has a beta of 1.47, which means the stock price is 47% more volatile than the S&P 500. AC Immune has a beta of 0.37 in contrast, indicating that its stock price is 63 per cent less volatile than the S&P 500.

Vertex Pharmaceuticals Incorporated is involved in the development and commercialisation of cystic fibrosis treatment therapies. SYMDEKO / SYMKEVI, ORKAMBI, and KALYDECO are marketed by the company to treat patients with cystic fibrosis who have specific mutations in their transmembrane conductivity regulator gene. It is also developing phase III clinical trialsVX-659andVX-445;VX-121, a phase I / II clinical trial cystic fibrosis transmembrane conductance regulator corrector;VX-150, an agent in phase IIb clinical trial for acute pain; CTX001 in phase I / II clinical trial for the treatment of beta-thalassemia and sickle cell disease; and a new drug candidate in phase I / II clinical trial; The company sells its products primarily to U.S. specialty pharmacy and specialty distributors, as well as specialty distributors and retail chains, and international hospitals and clinics. CRISPR Therapeutics AG has collaborated with Vertex Pharmaceuticals Inc.; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics. Launched in 1989, the company has its headquarters in Boston, Massachusetts.

AC Immune logoAC Immune SA, a biopharmaceutical company in the clinical stage, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of protein-associated neurodegenerative diseases. Its platforms SupraAntigen and Morphomer are designed to generate vaccines, antibodies, and small molecules that interact selectively with misfolded proteins common in a range of neurodegenerative diseases.